This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Review  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

Sympathetic Activation in Heart Failure and Its Treatment With -Blockade

Gregory S. Pepper, MD; Richard W. Lee, MD

Arch Intern Med. 1999;159:225-234.

Multiple models explaining the pathogenesis of heart failure have been put forth during the past 5 decades. These models were modified as clinical evidence supported or refuted their assumptions. During the past 2 decades, heart failure models emphasized the importance of neurohormonal systems in heart failure progression. The positive impact that angiotensin-converting enzyme inhibitors have had on mortality from heart failure has bolstered the neurohormonal theory. Attention recently has turned to the sympathetic nervous system and its potential deleterious effects on the cardiovascular system in heart failure. The sympathetic nervous system can negatively impact the cardiovascular system in heart failure in several ways, including down-regulating ₁-receptors, exerting direct toxic effects on the myocardium, and contributing to myocardial remodeling and life-threatening arrhythmias. -Adrenergic blockers have shown promise for reducing morbidity and mortality in heart failure, but definitive reductions in mortality remain to be shown by future investigations.

From the Division of Cardiovascular Diseases, Mayo Clinic Scottsdale, Scottsdale, Ariz.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mental Disorders, Quality of Care, and Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis of the National Heart Failure Project
Rathore et al.
Arch Gen Psychiatry 2008;65:1402-1408.
ABSTRACT | FULL TEXT  

Depression in Patients With Heart Failure: Prevalence, Pathophysiological Mechanisms, and Treatment
Thomas et al.
Crit Care Nurse 2008;28:40-55.
FULL TEXT  

Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF{alpha}-caspase signaling pathway
Fu et al.
Cardiovasc Res 2004;62:558-567.
ABSTRACT | FULL TEXT  

Norepinephrine induces apoptosis in neonatal rat endothelial cells via down-regulation of Bcl-2 and activation of {beta}-adrenergic and caspase-2 pathways
Fu et al.
Cardiovasc Res 2004;61:143-151.
ABSTRACT | FULL TEXT  

Depression and Risk of Heart Failure Among the Elderly: A Prospective Community-Based Study
Williams et al.
Psychosom. Med. 2002;64:6-12.
ABSTRACT | FULL TEXT  

Depression and Risk of Heart Failure Among Older Persons With Isolated Systolic Hypertension
Abramson et al.
Arch Intern Med 2001;161:1725-1730.
ABSTRACT | FULL TEXT  

Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist
Gomberg-Maitland et al.
Arch Intern Med 2001;161:342-352.
ABSTRACT | FULL TEXT  

Is the prognosis of heart failure improving?
Khand et al.
J Am Coll Cardiol 2000;36:2284-2286.
FULL TEXT  

Increased Plasma Norepinephrine Response to Yohimbine in Elderly Men
Petrie et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2000;55:155M-159.
ABSTRACT | FULL TEXT  

MYOCYTE CONTRACTILE DYSFUNCTION WITH HYPERTROPHY AND FAILURE: RELEVANCE TO CARDIAC SURGERY
Walker et al.
J. Thorac. Cardiovasc. Surg. 2000;119:388-400.
FULL TEXT